There are multiple chapters near you. Select your preferred chapter.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

The epilepsy treatment is now approved as an add-on therapy for patients aged ≥ 2 years, following an appeal against NICE’s initial rejection.

Staffing and certain compliance issues related to updated survey guidance coming in late March, particularly those that relate to patient discharges as ...